Cargando…

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial

INTRODUCTION: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised that empagliflozin reduces tissue sodium content in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolwelter, Julie, Kannenkeril, Dennis, Linz, Peter, Jung, Susanne, Nagel, Armin M., Bosch, Agnes, Ott, Christian, Bramlage, Peter, Nöh, Lisa, Schiffer, Mario, Uder, Michael, Achenbach, Stephan, Schmieder, Roland E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849317/ https://www.ncbi.nlm.nih.gov/pubmed/36289063 http://dx.doi.org/10.1007/s00392-022-02119-7

Ejemplares similares

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure
por: Bosch, Agnes, et al.
Publicado: (2023)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
por: Pietschner, R., et al.
Publicado: (2021)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study
por: Kolwelter, Julie, et al.
Publicado: (2022)

Is vascular remodelling in patients with chronic heart failure exaggerated?
por: Pietschner, Robert, et al.
Publicado: (2022)

Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction
por: Jung, Susanne, et al.
Publicado: (2021)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
por: Bosch, Agnes, et al.
Publicado: (2019)

Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure
por: Jung, Susanne, et al.
Publicado: (2021)

Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis
por: Staef, Mawadah, et al.
Publicado: (2023)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
por: Kannenkeril, Dennis, et al.
Publicado: (2018)

Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography
por: Jung, Susanne, et al.
Publicado: (2020)

Afferent neurons of the kidney with impaired firing pattern in inflammation – role of sodium currents?
por: Lale, Nena, et al.
Publicado: (2023)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Tolvaptan treatment in an adult Fontan patient with protein-losing enteropathy: a serial (23)Na-MRI investigation
por: Moosmann, Julia, et al.
Publicado: (2021)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
por: Anker, Stefan D., et al.
Publicado: (2018)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
por: Pennig, Jan, et al.
Publicado: (2019)

Neurogenic substance P—influences on action potential production in afferent neurons of the kidney?
por: Rodionova, Kristina, et al.
Publicado: (2021)

Myocardial infarction with a preserved ejection fraction—the impaired function of the cardio-renal baroreflex
por: Pickny, Lisa, et al.
Publicado: (2023)

Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol
por: Muller, Marie-Eve, et al.
Publicado: (2018)

Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study
por: Schmieder, Roland E, et al.
Publicado: (2012)

Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
por: Schmieder, Roland E, et al.
Publicado: (2009)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Publicado: (2022)

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial
por: Zanchi, Anne, et al.
Publicado: (2020)

Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass
por: Ferreira, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7l03q6591ng52k6lmo7uj1s2ia